CEO Joseph Dowling highlighted the company’s focus on scaling its business, achieving cost efficiencies, and transitioning to a global health and wellness company. He noted a revenue of $15.7 million ...
The average one-year price target for CapsoVision (NasdaqCM:CV) has been revised to $6.12 / share. This is an increase of 20.00% from the prior estimate of $5.10 dated November 7, 2025. The price ...
KENNESAW, Ga.—October 8, 2015—The overwhelming success of Heidelberg’s expanded and expanding digital portfolio includes the recent sale of its 600th Linoprint digital press. More than 150 of those ...
So CV Therapeutics won't play? We'll see about that: Astellas Pharma has a bully-boy gleam in its eye. You can almost hear it saying, "You'll play, buster. So help me, you'll play." Rejected in its $1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback